Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 11/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21369061 | 0.88 | GLS (0.78) | GLSHSD17B10ALDH1A1HPGDGAA | |
| SCHEMBL14987537 | 0.88 | GLS (0.86) | GLSHSD17B10ALDH1A1HPGDGAA | |
| SCHEMBL14987417 | 0.87 | GLS (0.76) | GLSHSD17B10ALDH1A1HPGDGAA | |
| SCHEMBL15727753 | 0.87 | GLS (0.76) | GLSHSD17B10ALDH1A1HPGDGAA | |
| SCHEMBL15727756 | 0.84 | GAA (0.73) | GLSHSD17B10ALDH1A1HPGDGAA | |
| SCHEMBL14987273 | 0.83 | GLS (1.00) | GLSHSD17B10MAPK1 | |
| SCHEMBL14986996 | 0.82 | GLS (0.90) | GLSALDH1A1 | |
| SCHEMBL15042405 | 0.81 | GLS (0.88) | GLSALDH1A1 | |
| SCHEMBL20033181 | 0.81 | GLS (0.73) | GLSHSD17B10GAAMAPK1 | |
| SCHEMBL15727757 | 0.80 | GLS (0.67) | GLSHSD17B10ALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | CALITHERA BIOSCIENCES INC. | 2020-05-28 | — | — | US | disclosed |
| US-20190315733-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. | 2019-10-17 | — | — | US | disclosed |
| US-10441587-B2 | Treatment of lung cancer with inhibitors of glutaminase | CALITHERA BIOSCIENCES, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-9938267-B2 | Heterocyclic inhibitors of glutaminase | CALITHERA BIOSCIENCES, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| WO-2018039442-A1 | TREATMENT OF CANCER WITH INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| US-20180055825-A1 | TREATMENT OF CANCER WITH INHIBITORS OF GLUTAMINASE | LIANG YU (US) | 2018-03-01 | — | — | US | disclosed |
| WO-2016164401-A1 | TREATMENT OF LUNG CANCER WITH INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016160980-A1 | METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160287564-A1 | METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160287585-A1 | Treatment of Lung Cancer with Inhibitors of Glutaminase | CALITHERA BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20150258082-A1 | COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. | 2015-09-17 | — | — | US | disclosed |
| WO-2015138902-A1 | COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140369961-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. | 2014-12-18 | — | — | US | disclosed |
| WO-2014089048-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013078123-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885HSD17B10 521/4885ALDH1A1 639/4885 |
| US-20190315733-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885HSD17B10 521/4885ALDH1A1 639/4885 |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | GLS, GLS2, GLUL | GLS 1/4885HSD17B10 521/4885ALDH1A1 639/4885 |
| US-10441587-B2 | Treatment of lung cancer with inhibitors of glutaminase | KRAS, GLS, GLUL | GLS 2/4885HSD17B10 1739/4885ALDH1A1 885/4885 |
| US-20160287585-A1 | Treatment of Lung Cancer with Inhibitors of Glutaminase | KRAS, GLS, GLUL | GLS 2/4885HSD17B10 1739/4885ALDH1A1 885/4885 |
| US-20140369961-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885HSD17B10 521/4885ALDH1A1 639/4885 |
| US-20180055825-A1 | TREATMENT OF CANCER WITH INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885HSD17B10 818/4885ALDH1A1 293/4885 |
| US-20160287564-A1 | METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS | GLS, GLS2, GLUL | GLS 1/4885HSD17B10 1179/4885ALDH1A1 1051/4885 |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885HSD17B10 619/4885ALDH1A1 263/4885 |
| US-20150258082-A1 | COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS | GLS, GLUL, GLS2 | GLS 1/4885HSD17B10 1937/4885ALDH1A1 704/4885 |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885HSD17B10 521/4885ALDH1A1 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.